Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPVDCVax in HPV-Positive Oropharyngeal Cancer
NCT06007092Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jul 2023
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of CD40.HVac in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Gustave Roussy. Started Jul 2023; status: completed.
02
Drugs
CD40.HVac
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06007092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007092.